Treatment options after sorafenib failure in patients with hepatocellular carcinoma

被引：31

作者：

El Dika, Imane ^{[1
]}

Abou-Alfa, Ghassan K. ^{[1
,2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 300 East 66th St, New York, NY 10065 USA

[2] Weill Cornell Med Coll, New York, NY USA

来源：

CLINICAL AND MOLECULAR HEPATOLOGY | 2017年 / 23卷 / 04期

关键词：

Hepatocellular carcinoma; Antiangiogenic therapy; MET-inhibitors; Immunotherapy; RECOMBINANT HUMAN ARGINASE; PHASE-II; HEPATITIS-C; 2ND-LINE TREATMENT; FUTURE-DIRECTIONS; CLINICAL-TRIAL; DOUBLE-BLIND; THERAPY; ANGIOGENESIS; EFFICACY;

D O I：

10.3350/cmh.2017.0108

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellular carcinoma in the world, continued efforts are ongoing to look for efficient upfront, second line, or combination therapies. Herein we review the most relevant to date published literature on treatment options beyond sorafenib, reported studies, ongoing investigational efforts, and possibilities for future studies in advanced hepatocellular carcinoma.

引用

页码：273 / 279

页数：7

共 47 条

[1] Phase II study of sorafenib in patients with advanced hepatocellular carcinoma [J].

Abou-Alfa, Ghassan K. ;

Schwartz, Lawrence ;

Ricci, Sergio ;

Amadori, Dino ;

Santoro, Armando ;

Figer, Arie ;

De Greve, Jacques ;

Douillard, Jean-Yves ;

Lathia, Chetan ;

Schwartz, Brian ;

Taylor, Ian ;

Moscovici, Marius ;

Saltz, Leonard B. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4293-4300

[2] Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC) [J].

Abou-Alfa, Ghassan K. ;

Qin, Shukui ;

Ryoo, Baek-Yeol ;

Lu, Sheng-Nan ;

Yen, Chia-Jui ;

Feng, Yin-Hsun ;

Lim, Ho Yeong ;

Izzo, Francesco ;

Colombo, Massimo ;

Sarker, Debashis ;

Bolondi, Luigi ;

Vaccaro, Gina M. ;

Harris, William Proctor ;

Chen, Zhendong ;

Hubner, Richard ;

Meyer, Tim ;

Bomalaski, John S. ;

Lin, ChenChun ;

Chao, Yee ;

Chen, Li-Tzong .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[3] Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426). [J].

Abou-Alfa, Ghassan K. ;

Cheng, Ann-Lii ;

Meyer, Tim ;

El-Khouelry, Anthony B. ;

Ikeda, Masafumi ;

Chun, Hoo Geun ;

Falvre, Sandrine J. ;

Furuse, Junji ;

Knox, Jennifer J. ;

Okusaka, Takuji ;

Ping, Jerry ;

Borgman-Hagey, Anne E. ;

Kelley, Robin Kate .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[4] Selection of Patients with Hepatocellular Carcinoma for Sorafenib [J].

Abou-Alfa, Ghassan K. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 (04) :397-403

[5] Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial [J].

Alberts, Steven Robert ;

Fitch, Tom R. ;

Kim, George P. ;

Morlan, Bruce W. ;

Dakhil, Shaker R. ;

Gross, Howard M. ;

Nair, Suresh .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (04) :329-333

[6] Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging [J].

Allen, Michael D. ;

Phuong Luong ;

Hudson, Chantelle ;

Leyton, Julius ;

Delage, Barbara ;

Ghazaly, Essam ;

Cutts, Rosalind ;

Yuan, Ming ;

Syed, Nelofer ;

Lo Nigro, Cristiana ;

Lattanzio, Laura ;

Chmielewska-Kassassir, Malgorzata ;

Tomlinson, Ian ;

Roylance, Rebecca ;

Whitaker, Hayley C. ;

Warren, Anne Y. ;

Neal, David ;

Frezza, Christian ;

Beltran, Luis ;

Jones, Louise J. ;

Chelala, Claude ;

Wu, Bor-Wen ;

Bomalaski, John S. ;

Jackson, Robert C. ;

Lu, Yong-Jie ;

Crook, Tim ;

Lemoine, Nicholas R. ;

Mather, Stephen ;

Foster, Julie ;

Sosabowski, Jane ;

Avril, Norbert ;

Li, Chien-Feng ;

Szlosarek, Peter W. .

CANCER RESEARCH, 2014, 74 (03) :896-907

[7]

[Anonymous], J CLIN ONCOL

[8] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[9] Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial [J].

Bruix, J. ;

Merle, P. ;

Granito, A. ;

Huang, Y. -H. ;

Bodoky, G. ;

Yokosuka, O. ;

Rosmorduc, O. ;

Breder, V. ;

Gerolami, R. ;

Masi, G. ;

Paul, J. Ross ;

Qin, S. ;

Song, T. ;

Bronowicki, J. -P. ;

Ollivier-Hourmand, I. ;

Kudo, M. ;

LeBerre, M. -A. ;

Baumhauer, A. ;

Meinhardt, G. ;

Han, G. .

ANNALS OF ONCOLOGY, 2016, 27 :140-+

[10] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

← 1 2 3 4 5 →